Re: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal

in response to

German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal

BearDownAZ

posted on Jun 03, 2021 12:33PM

EndPoints article on the Constellation Deal.

UPDATED: MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

"MorphoSys is paying $34 a share for the Cambridge, MA-based Constellation, bagging 2 lead drugs: pelabresib (CPI-0610), billed as a potential first and best-in-class BET inhibitor, and CPI-0209, a second-generation EZH2 inhibitor, that is in mid-to late-stage development."

https://endpts.com/breaking-morphosys-swoops-in-with-a-1-7b-deal-to-buy-constellation-adds-2b-plus-in-royalty-pact/

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply